Introduction and objectives: Nitric oxide synthase (NOS3) and dimethylarginine dimethylaminohydrolase 2 (DDAH2) polymorphisms are associated with reduced nitric oxide (NO) synthesis and endothelial dysfunction, increasing the risk of cardiovascular disease (CVD). Here, NOS3 is linked to cardiovascular disorder.